Apigenin sensitizes colon cancer cells to antitumor activity of abt-263

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2640-2650

  Shao, Huanjie ^a   Jing, Kai ^a   Mahmoud, Esraa ^a   Huang, Haihong ^b   Fang, Xianjun ^a   Yu, Chunrong ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c Well Testing and Oil Extraction Company   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; BIM PROTEIN; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MCL 1; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APIGENIN; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890475550     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0066     Document Type: Article

References (44)

1. Zhong Y, Krisanapun C, Lee SH, Nualsanit T, Sams C, Peungvicha P, et al. Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer 2010;46:3365-74
2. WangQ, Yao X,WenG, Fan Q, Li Y, Fu X, et al. Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and upregulated FADD expression. Oncol Lett 2011;2:43-7
3. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007;30:233-45
4. Shukla S, Gupta S. Apigenin: A promising molecule for cancer prevention.Pharm Res 2010;27:962-78
5. Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol,luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 2001;49:3106-12
6. Bruno A, Siena L, Gerbino S, Ferraro M, Chanez P, Giammanco M, et al.Apigenin affects leptin/leptin receptor pathway and induces cell apoptosis in lung adenocarcinoma cell line. Eur J Cancer 2011;47:2042-51
7. Choi EJ, Kim GH. Apigenin induces apoptosis through a mitochondria/ caspase-pathway in human breast cancer MDA-MB-453 cells. J Clin Biochem Nutr 2009;44:260-5
8. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 2001;287:914-20
9. Budhraja A, Gao N, Zhang Z, Son YO, Cheng S, Wang X, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 2012;11:132-42
10. Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Köoohler R, et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis 2011;2:e182
11. Au A, Li B, Wang W, Roy H, Koehler K, Birt D. Effect of dietary apigenin on colonicornithine decarboxylase activity, aberrant crypt foci formation,and tumorigenesis in different experimental models. Nutr Cancer 2006;54:243-51
12. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE.Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46:249-79
13. Brzezianska E, Pastuszak-Lewandoska D. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci 2011;16:422-39
14. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR,B€asecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011;25:1080-94
15. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C,Gonzáalez-Baróon M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204
16. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76
17. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor in signaling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004;68:1003-15
18. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 2012;40:639-44
19. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH,B€asecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance,apoptosis and sensitivity to targeted therapy. Cell Cycle 2010;9:1781-91
20. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL.Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008;118:3651-9
21. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, et al. Sorafenib induces apoptosis of AML cells via Bimmediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-18
22. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic aleukemia. Leukemia 2011;25:781-91
23. Qian J, Zou Y, Rahman JS, Lu B, Massion PP. Synergy between PI3Kinase/AKT pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009;8:101-9
24. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al.ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8
25. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al.'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 Oncogene 2007;26:3972-9
26. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13
27. Tang H, Shao H, Yu C, Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.Biochem Pharmacol 2011;82:1066-72
28. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, et al. Discovery of marinopyrroleA (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012;287:10224-35
29. Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, et al. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol 2012;56:176-83
30. Hou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55
31. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K,et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
32. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R,et al. Potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-2219, AZD6244 (ARRY-142886)
33. Sharma G, Kar S, Palit S, Das PK. 18b-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J Cell Physiol 2012;227:1923-31
34. Bhalla S, Evens AM, Dai B, Prachand S, Gordon LI, Gartenhaus RB.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.Blood 2011;118:1052-61
35. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: A novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384-95
36. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999;18:2330-41
37. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99
38. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91
39. Iglesias-Serret D, PiquéM, Gil J, Pons G, López JM. Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 2003;417:141-52
40. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004;23:5301-15
41. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60
42. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-17
43. Araki T, Hayashi M, Watanabe N, Kanuka H, Yoshino J, Miura M, et al. Down-regulation of Mcl-1 by inhibition of the PI3-K/Akt pathway is required for cell shrinkage-dependent cell death. Biochem Biophys Res Commun 2002;290:1275-81
44. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-55